KRC-00715

MedChem Express

KRC-00715

9

Research Use Only

C25H25F3N8O3

542.51

KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models[1].

FC(F)(F)C1=C(OCCN2CCOCC2)C=CC(C3=NC(N(CC4OC(C=CC=N5)=C5NC4)N=N6)=C6N=C3)=C1

12352200